VivoSeq
Gastroenterology

Anal Fissure

27

Pipeline Programs

3

Active Trials

16

Companies Involved

Anal fissure is an emerging landscape with 27 programs across 16 companies. The most active players are Omnivium, RDD Pharma Ltd, Vitae Pharmaceuticals Inc., an Allergan affiliate. 11 therapies are approved with 4 more in late-stage development.

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

0/100

Mech. Concentration

38/100

Completion Rate

78/100

Attrition Rate

16/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

97%

Small molecule

36 of 37 classified programs — the dominant modality here.

3%ALL OTHERSGene therapy13%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Trial Status

31

clinical trials

Completed18 · 58%
Unknown status5 · 16%
Terminated3 · 10%
Recruiting3 · 10%
Withdrawn2 · 6%

Trial Activity

31 trials

Efficacy Study of Dysport® in the Treatment of Anal Fissure.
Completed·Ipsen logoIpsen·Phase 2·NCT00210444·168 enrolled
Diltiazem Hydrochloride Cream for Anal Fissure
Completed·SS.L.A. Pharma AG·Phase 3·NCT01217515·465 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)